Iovance Biotherapeutics(GB:0JDK)
$8.03+0.04 (+0.56%)
GB:0JDK
Iovance Biotherapeutics ownership
$8.03
At close:+0.04 (+0.56%)
Iovance Biotherapeutics (0JDK) Ownership - Who Owns Iovance Biotherapeutics?
5 Followers
Iovance Biotherapeutics (0JDK) Ownership Overview
- 0.33% Insiders
- 13.56% Mutual Funds
- 2.50% Other Institutional Investors
- 17.56% ETFs
- 66.05% Public Companies and Individual Investors
The ownership structure of Iovance Biotherapeutics (GB:0JDK) stock is a mix of institutional, retail, and individual investors. Approximately 33.62% of the company’s stock is owned by Institutional Investors, 0.33% is owned by Insiders, and 66.05% is owned by Public Companies and Individual Investors.
The ownership structure of Iovance Biotherapeutics (GB:0JDK) stock is a mix of institutional, retail, and individual investors. Approximately 33.62% of the company’s stock is owned by Institutional Investors, 0.33% is owned by Insiders, and 66.05% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Perceptive Advisors Llc | $416,909 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 36,957,681 | Institution | 7.99% | 296,585,390 |
| Vanguard | 29,906,687 | Institution | 6.46% | 240,001,163 |
| Vanguard Index Funds | 25,730,154 | Institution | 5.56% | 206,484,486 |
| Ishares | 21,372,199 | Institution | 4.62% | 171,511,897 |
| Spdr | 13,768,021 | Institution | 2.98% | 110,488,369 |
| Fidelity Salem Street Trust | 4,964,410 | Institution | 1.07% | 39,839,390 |
| Tiaa-cref Funds | 4,354,851 | Institution | 0.94% | 34,947,679 |
| Fidelity Concord Street Trust | 3,862,069 | Institution | 0.83% | 30,993,104 |
| Northern Lights Fund Trust Ii | 3,377,261 | Institution | 0.73% | 27,102,520 |
| Dfa | 3,195,159 | Institution | 0.69% | 25,641,151 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 25,730,154 | Institution | 5.56% | 206,484,486 |
| Fidelity Salem Street Trust | 4,964,410 | Institution | 1.07% | 39,839,390 |
| Tiaa-cref Funds | 4,354,851 | Institution | 0.94% | 34,947,679 |
| Fidelity Concord Street Trust | 3,862,069 | Institution | 0.83% | 30,993,104 |
| Northern Lights Fund Trust Ii | 3,377,261 | Institution | 0.73% | 27,102,520 |
| Delaware Group Equity Funds V | 2,940,670 | Institution | 0.64% | 23,598,877 |
| Dfa Investment Dimensions Group Inc | 2,747,105 | Institution | 0.59% | 22,045,518 |
| Vanguard Scottsdale Funds | 2,687,801 | Institution | 0.58% | 21,569,603 |
| Vanguard Horizon Funds | 2,464,754 | Institution | 0.53% | 19,779,651 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,439,842 | Institution | 0.31% | 11,554,732 |
FAQ
Who Owns Iovance Biotherapeutics (GB:0JDK)?
According to the latest TipRanks data, approximately 33.62% of the company's stock is held by institutional investors, 0.33% is held by insiders, and 66.05% is held by public companies and individual investors.
What percentage of Iovance Biotherapeutics (GB:0JDK) stock is held by institutional investors?
According to the latest TipRanks data, approximately 33.62% of Iovance Biotherapeutics (GB:0JDK) stock is held by institutional investors: 13.56% by mutual funds, 17.56% by ETFs and 2.50% by other institutional investors.
What percentage of Iovance Biotherapeutics (GB:0JDK) stock is held by retail investors?
According to the latest TipRanks data, approximately 66.05% of Iovance Biotherapeutics (GB:0JDK) stock is held by public companies and individual investors.
Who owns the most shares of Iovance Biotherapeutics (GB:0JDK)?
BlackRock, Inc. owns the most shares of Iovance Biotherapeutics (GB:0JDK).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
